Basic Information
| LncRNA/CircRNA Name | PCAT1 |
| Synonyms | LPCAT1, AGPAT10, AGPAT9, AYTL2, LPCAT-1, PFAAP3, lpcat, lysoPAFAT, PCAT-1 |
| Region | GRCh38_8:126556323-127419050 |
| Ensemble | ENSG00000253438 |
| Refseq | NR_045262 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | Cisplatin | |
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | gastric cancer |
| ICD-0-3 | C16 |
| Methods | qPCR, Western blot, Luciferase reporter assay, RIP, etc. |
| Sample | GC tissues, fetal gastric epithelial cell (GES-1) and human GC cell lines (BGC823 and SGC7901) |
| Expression Pattern | up-regulated |
| Function Description | PCAT 1 was overexpressed in CDDP resistant GC tumor tissues and cell lines. High expression of PCAT 1 was closely correlated with short overall survival in patients with GC. Downregulation of PCAT 1 resensitized CDDP resistant GC cells to cisplatin. In addition, PCAT 1 epigenetically silenced PTEN through binding to the histone methyltransferase enhancer of zeste homolog 2 (EZH2), thus increasing H3K27me3. More importantly, PTEN silencing counteracted PCAT 1 knockdown mediated enhancement in cisplatin sensitivity of CDDP resistant GC cells. In summary, PCAT 1 led to cisplatin resistance in GC cells through epigenetically suppressing PTEN expression, providing a novel therapeutic strategy for GC patients with chemoresistance. |
| Pubmed ID | 31478258 |
| Year | 2019 |
| Title | PCAT-1 contributes to cisplatin resistance in gastric cancer through epigenetically silencing PTEN via recruiting EZH2 |
External Links
| Links for PCAT1 | GenBank HGNC NONCODE |
| Links for gastric cancer | OMIM COSMIC |